奥扎格雷对急性冠脉综合征患者血清sCD40L的影响  

The influence of azagral sodium to the sCD40L in patients with ACS

作　　者：罗小岚[1] 赵水平[1] 周宏年[1] 

机构地区：[1]中南大学湘雅二医院,湖南长沙410011

出　　处：《医学临床研究》2008年第3期417-418,共2页Journal of Clinical Research

摘　　要：【目的】观察奥扎格雷对急性冠脉综合征(acute coronary syndrome,ACS)患者血清可溶性白细胞分化抗原40配体(sCD40L)含量的影响。【方法】选择80例ACS病人,其中急性心肌梗死(acute myocardiolinfarction,AMI)40例,不稳定心绞痛(unstable angina pectoris,UAP)40例,随机分为治疗组(常规治疗加奥扎格雷,n=40)和对照组(常规治疗,n=40),分别测定治疗前后病人血清sCD40L的含量,进行统计分析。【结果】两组病人治疗后的血清sCD40L明显下降,奥扎格雷治疗组血清sCD40L含量下降幅度降低(65%)大于对照组降低(47%)。【结论】用奥扎格雷治疗ACS病人,能显著降低血清CD40L的含量。[Objective]To observe the influence of azagral sodium to the plasma soluble CD40 ligand （sCD40L） in patients with acute coronary syndrome （ACS）. [Methods]The subjects included 80 patients with ACS in which 40 patients with acute myocardiol infarction （AMI） and 40 patients with unstable angina pectoris （UAP）. The patients were divided into two groups, treatment group and control group. There were 40 cases in each group. All patients were measured the plasma levels of sCD40L before and after treatment with medcine. [Results]The plasma levels of sCD40L in the treatment group were significantly reduced from that of the control group （ P 〈0. 05）. [Conclusion]With the treatment of azagral sodium in patients with ACS, the plasma levels of sCD40L were remarkably inhibited.

关 键 词：冠状动脉疾病/药物疗法 急性病 甲基丙烯酸盐/治疗应用 综合征 抗原 CD40/血液 

分 类 号：R543.305.3[医药卫生—心血管疾病]